



WU/Pfizer Centers for Therapeutic Innovation Call for Proposals (Round Two)

[Pfizer's Centers for Therapeutic Innovation \(CTI\)](#) has announced the second call for proposals through its partnership with Washington University. CTI is a unique program that collaborates with leading academic medical centers, the NIH, and foundations to speed the translation of novel targets to the clinic.

As part of the Pfizer CTI/Washington University research agreement, Washington University researchers are eligible to apply for funding to support specific research projects. If a project is selected, School of Medicine investigators would have access to Pfizer's resources, scientific equipment, and opportunities to collaborate with Pfizer scientists, who have extensive expertise in drug development.

This is the second call for proposals. Several Washington University groups who responded to the first call for proposals are now developing full proposals with Pfizer.

Specific criteria to this second call for proposals are:

- The therapeutic interests of this round include **oncology, inflammation and immune disorders, cardiovascular and metabolic diseases, neuroscience and rare monogenetic disorders.**
- The anticipated clinical modality should be **large molecule bio-therapeutics** (antibodies, proteins, fusion proteins and antibody conjugates).
- Please note that RNAi, CRISPR technologies, nanoparticles and small molecules are **out of scope** for this round. See the attached CTI Flyer for more information on the program and the Pre-Proposal Template for details about the pre-proposal.

Application Process

1. A non-confidential two-to-three page Pre-proposal is submitted by **October 13th, 2017** to internalselections@wustl.edu. This preproposal will be reviewed by the Office of Technology Management to protect your intellectual property and ensure there are no accidental enabling disclosures.
2. Following a review period of approximately 10 weeks, Pfizer CTI will invite some investigators to submit a full proposal. At this stage, investigators will also be paired with a Pfizer co-PI.
3. After a second review period of approximately 10 weeks, a final decision will be reached regarding which projects Pfizer CTI will partner on.

Pre-proposal help

A Washington University committee is in place to help our investigators navigate this funding opportunity and increase their likelihood of success. Members of the committee are:

Karen Seibert kareenseibert@wustl.edu
Thad Stappenbeck stappenb@wustl.edu
Michael Kinch michael.kinch@wustl.edu
Leena Prabhu l.prabhu@wustl.edu
Pat Gregory patgregory@wustl.edu

Attachments:

 [2017 CFP Large Flyer_WashU.pdf](#)

 [CTI PreProposal Template 2017.docx](#)